Form 4: Voyager Therapeutics CEO Sells Shares for Tax Obligations

Voyager Therapeutics CEO Alfred Sandrock sold 14,197 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Alfred Sandrock, President and CEO, and a Director of Voyager Therapeutics, Inc. (VYGR), sold 14,197 shares of common stock.
• The transaction occurred on February 24, 2026, at a weighted average price of $3.79 per share, with prices ranging from $3.61 to $3.86.
• The sale was non-discretionary, executed pursuant to a durable automatic sale instruction adopted on May 12, 2025.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 21, 2026.
• Following this transaction, Alfred Sandrock beneficially owns 484,060 shares of common stock.
• The transaction was made under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and pre-planned for tax purposes, not indicative of a change in management's outlook or company fundamentals.

Positives

• The sale was a non-discretionary transaction, pre-arranged under a Rule 10b5-1 plan, indicating it was not based on new material non-public information.

Negatives

• The sale represents a reduction in the CEO's direct ownership, although it was for tax purposes and not a discretionary decision.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Alfred Sandrock's sale of shares was pursuant to a durable automatic sale instruction adopted on May 12, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting, and does not represent a discretionary trade.

Industry Context

StockSavvy.ai notes that such 'sell-to-cover' transactions are common for executives receiving equity compensation and are typically pre-arranged under Rule 10b5-1 plans to avoid accusations of insider trading. This type of transaction is generally viewed as a routine administrative event rather than a signal of management's sentiment about the company's future.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.

Key Dates

Recommendation

The transaction is a routine, non-discretionary 'sell-to-cover' for tax obligations related to RSU vesting, executed under a pre-established 10b5-1 plan. It does not provide new information regarding the company's operational performance or future prospects, thus maintaining a 'hold' recommendation.

Keywords

Voyager Therapeutics, VYGR, Alfred Sandrock, Insider Sale, Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, Tax Withholding, 10b5-1 Plan